CO6280483A2 - Forma cristalina 1 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n`-(2-fluoro-5-metilfenil)urea toluenato - Google Patents
Forma cristalina 1 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n`-(2-fluoro-5-metilfenil)urea toluenatoInfo
- Publication number
- CO6280483A2 CO6280483A2 CO10049265A CO10049265A CO6280483A2 CO 6280483 A2 CO6280483 A2 CO 6280483A2 CO 10049265 A CO10049265 A CO 10049265A CO 10049265 A CO10049265 A CO 10049265A CO 6280483 A2 CO6280483 A2 CO 6280483A2
- Authority
- CO
- Colombia
- Prior art keywords
- indazol
- methylphenyl
- fluoro
- phenyl
- urea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Forma cristalina 1 de N-(4-(3-amino-1H-indazol-4- il)fenil)-N'-(2-fluoro-5-metilfenil)urea tolueneato que, cuando se mide a aproximadamente -100°C en el sistema cristalino monoclínico y el grupo espacial P21/C con radiación a 0,7107 Å, se caracteriza por los respectivos valores de los parámetros de red a, b y c de 13,80Å ± 0,01Å, 8,910Å ± 0,007Å y 19,87Å ± 0,02Å y los respectivos valores a, ß y ? de aproximadamente 90°, 103,75° ± 0,01° y 90°.2.- Un proceso para elaborar la forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea toluenato.proveer una mezcla que comprende N-(4-(3-amino-1H-indazol-4-il)fenil)-N'-(2-fluoro-5-metilfenil)urea y tolueno, en donde la N-(4-(3-amino-1H-indazol-4-il)fenil)-N´-(2-fluoro-5- metilfenil)urea está completamente disuelta en el tolueno; y causar que la forma cristalina 1 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N'-(2-fluoro-5-metilfenil)urea toluenato exista en la mezcla, donde dicha forma cristalina 1 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N'-(2-fluoro-5-metilfenil)urea toluenato, cuando se mide a aproximadamente -100°C en el sistema cristalino monoclínico y el grupo espacial P21/C con radiación a 0.7107 Å, se caracteriza por los respectivos valores de los parámetros de red a, b y c de 13,80Å ± 0,01Å, 8,910Å ± 0,007Å y 19,87Å ± 0,02Å y valores respectivos de a, ß y ? de aproximadamente 90°, 103,75° ± 0,01° y 90°.3.- El proceso de la reivindicación 2 que además comprende aislar la forma cristalina 1 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea toluenato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98124307P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6280483A2 true CO6280483A2 (es) | 2011-05-20 |
Family
ID=40242659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10049265A CO6280483A2 (es) | 2007-10-19 | 2010-04-27 | Forma cristalina 1 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n`-(2-fluoro-5-metilfenil)urea toluenato |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7943782B2 (es) |
| EP (1) | EP2195297A1 (es) |
| JP (1) | JP2011500706A (es) |
| KR (1) | KR20100102098A (es) |
| CN (1) | CN101827823B (es) |
| AU (1) | AU2008312532A1 (es) |
| BR (1) | BRPI0818343A2 (es) |
| CA (1) | CA2699353A1 (es) |
| CO (1) | CO6280483A2 (es) |
| CR (1) | CR11386A (es) |
| DO (1) | DOP2010000116A (es) |
| GT (1) | GT201000101A (es) |
| MX (1) | MX2010004289A (es) |
| MY (1) | MY153098A (es) |
| PA (1) | PA8800501A1 (es) |
| RU (1) | RU2010119917A (es) |
| SG (1) | SG185326A1 (es) |
| UA (1) | UA99487C2 (es) |
| WO (1) | WO2009052229A1 (es) |
| ZA (1) | ZA201002092B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| JP2017524034A (ja) | 2014-08-08 | 2017-08-24 | フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． | 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL373788A1 (en) * | 2002-05-10 | 2005-09-19 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of gatifloxacin |
| US7531551B2 (en) * | 2003-05-08 | 2009-05-12 | Ivax Pharmaceuticals S.R.O. | Polymorphs of cabergoline |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| JP4810427B2 (ja) * | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| DE102005033100B3 (de) * | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| JP4989476B2 (ja) * | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| US20070104780A1 (en) | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| JP2009521493A (ja) * | 2005-12-23 | 2009-06-04 | アルコン，インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 |
| JP2009523806A (ja) * | 2006-01-20 | 2009-06-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物 |
| EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,964 patent/US7943782B2/en not_active Expired - Fee Related
- 2008-10-16 WO PCT/US2008/080066 patent/WO2009052229A1/en active Application Filing
- 2008-10-16 AU AU2008312532A patent/AU2008312532A1/en not_active Abandoned
- 2008-10-16 BR BRPI0818343A patent/BRPI0818343A2/pt not_active IP Right Cessation
- 2008-10-16 UA UAA201005821A patent/UA99487C2/ru unknown
- 2008-10-16 RU RU2010119917/04A patent/RU2010119917A/ru not_active Application Discontinuation
- 2008-10-16 CN CN2008801119449A patent/CN101827823B/zh not_active Expired - Fee Related
- 2008-10-16 CA CA2699353A patent/CA2699353A1/en not_active Abandoned
- 2008-10-16 JP JP2010530092A patent/JP2011500706A/ja active Pending
- 2008-10-16 SG SG2012078200A patent/SG185326A1/en unknown
- 2008-10-16 MY MYPI20101652 patent/MY153098A/en unknown
- 2008-10-16 KR KR1020107010994A patent/KR20100102098A/ko not_active Application Discontinuation
- 2008-10-16 EP EP08839149A patent/EP2195297A1/en not_active Withdrawn
- 2008-10-16 MX MX2010004289A patent/MX2010004289A/es active IP Right Grant
- 2008-10-17 PA PA20088800501A patent/PA8800501A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02092A patent/ZA201002092B/en unknown
- 2010-04-16 GT GT201000101A patent/GT201000101A/es unknown
- 2010-04-16 DO DO2010000116A patent/DOP2010000116A/es unknown
- 2010-04-23 CR CR11386A patent/CR11386A/es not_active Application Discontinuation
- 2010-04-27 CO CO10049265A patent/CO6280483A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7943782B2 (en) | 2011-05-17 |
| UA99487C2 (xx) | 2012-08-27 |
| MY153098A (en) | 2014-12-31 |
| ZA201002092B (en) | 2011-11-30 |
| PA8800501A1 (es) | 2009-05-15 |
| AU2008312532A1 (en) | 2009-04-23 |
| WO2009052229A1 (en) | 2009-04-23 |
| EP2195297A1 (en) | 2010-06-16 |
| RU2010119917A (ru) | 2011-11-27 |
| CN101827823A (zh) | 2010-09-08 |
| KR20100102098A (ko) | 2010-09-20 |
| CN101827823B (zh) | 2012-10-03 |
| US20090105486A1 (en) | 2009-04-23 |
| MX2010004289A (es) | 2010-04-30 |
| CA2699353A1 (en) | 2009-04-23 |
| CR11386A (es) | 2010-08-18 |
| JP2011500706A (ja) | 2011-01-06 |
| BRPI0818343A2 (pt) | 2017-05-23 |
| DOP2010000116A (es) | 2010-05-31 |
| GT201000101A (es) | 2012-03-26 |
| SG185326A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082600A1 (es) | Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras | |
| CO6280483A2 (es) | Forma cristalina 1 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n`-(2-fluoro-5-metilfenil)urea toluenato | |
| JP2009144170A5 (es) | ||
| EA201000562A1 (ru) | Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы | |
| AR069364A1 (es) | Derivados heterociclicos que modulan la miosina del musculo liso y/o la miosina no muscular y composiciones farmaceuticas que los contienen | |
| GT201200333A (es) | Dispersiones sòlidas que contienen inhibidores de quinasas | |
| ES2604191T3 (es) | Inhibidores de tirosina quinasas | |
| NO20084912L (no) | Bisykliske derivater som CETP-inhibitorer | |
| PE20080058A1 (es) | Derivados de azol con actividad en dgat1 | |
| AR062176A1 (es) | Derivados de nicotinamida, una composicion farmaceutica que los comprende y su uso para tratar enfermedades asociadas con miosina de musculo liso o miosina no muscular | |
| BR112015023434A8 (pt) | compostos inibidores de histona deacetilase, seu uso e composição farmacêutica que os compreende | |
| AR069886A1 (es) | Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida | |
| BR112013028487A2 (pt) | inibidores do vírus da hepatite c | |
| CO5700735A2 (es) | Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas | |
| PE20110830A1 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas | |
| EA201000070A1 (ru) | Модуляторы калликреина 7 | |
| PE20181373A1 (es) | Metodo de preparacion de una sustancia de p-fenilendiamina sustituida con arilo | |
| BR112015023399A8 (pt) | inibidores de hdac, seu uso e composição farmacêutica | |
| BRPI0508471A8 (pt) | compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos | |
| MX2007005348A (es) | Formas amorfas y polimorficas de sodio de telmisartan. | |
| ECSP10010176A (es) | Productos quimioterapéuticos cristalinos | |
| ECSP10010175A (es) | Productos quimioterapéuticos cristalinos | |
| CL2008003091A1 (es) | Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero. | |
| CY1122772T1 (el) | Πολυμορφα του υδροχλωρικου 4-μεθυλβενζοϊκου 4-[2-διμεθυλαμινο-1-(1-υδροξυκυκλοεξυλ)αιθυλ]φαινυλεστερα, μεθοδοι για την παρασκευη αυτων και χρηση αυτων | |
| CL2008003090A1 (es) | Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |